Gregory P. Pogue

IC^2 Institute, The University of Texas at Austin

Gregory Pogue

Dr. Gregory Pogue is Senior Research Scientist in the IC2 Institute of the University of Texas at Austin as where he leads research and implementation programs surrounding technology commercialization, early venture creation and entrepreneurship. Commercialization programs in Portugal, Mexico and several biomedical initiatives are current areas of focus.

Before coming to the University of Texas, Dr. Pogue served as Vice President of Business Development for Emergent Technologies, Inc. (ETI), and President of Receptor Logic, Inc. and Pure Protein, L.L.C. As Vice President of Business Development at Emergent Technologies, Dr. Pogue is responsible for evaluating the commercial potential of new technologies, determining both technical and market trajectories, and building partnerships to effectively commercialize products. In this capacity, Dr. Pogue was the catalyst behind the business negotiations and technical management of the strategic relationship between ETI and Merck & Co. purposed to identify novel strategies for siRNA drug delivery. Under his leadership, Receptor Logic and Pure Protein have forged partnerships with four Fortune 500 companies, obtained >$3M in competitive grant funding, including a $1.8M Oklahoma EDGE grant, and successfully competed for a $2M award from the Texas Emerging Technology Fund. Dr. Pogue brings over twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. Dr. Pogue most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises.

Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the US FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Before joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities. He holds a B.S. from Midwestern State University and a Ph.D. from Texas A&M University. Pogue has published >40 original scientific articles and reviews, is an inventor on 17 U.S. patents, and is a frequent invited speaker at national and international scientific meetings.